Phathom Pharmaceuticals (PHAT) Free Cash Flow (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Free Cash Flow for 9 consecutive years, with -$1.9 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Free Cash Flow rose 96.93% year-over-year to -$1.9 million; the TTM figure through Jun 2026 stood at -$38.0 million (up 86.18% YoY), while the FY2025 annual figure was -$168.0 million, up 37.06% from the prior year.
• Free Cash Flow rose to -$1.9 million in Q2 2026 per PHAT's latest filing, from -$15.8 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$1.9 million in Q2 2026 and bottomed at -$85.0 million in Q1 2025.
• Historically, Free Cash Flow has averaged -$41.1 million across 5 years, with a median of -$40.7 million in 2022.
• Annual changes were most pronounced in 2024 — Free Cash Flow plunged 218.68% — and 2026, when it surged 96.93%.
• Phathom Pharmaceuticals' Free Cash Flow stood at -$41.5 million in 2022, then fell by 1.27% to -$42.0 million in 2023, then tumbled by 51.17% to -$63.5 million in 2024, then surged by 90.41% to -$6.1 million in 2025, then soared by 68.27% to -$1.9 million in 2026.
• Business Quant data shows PHAT's Free Cash Flow at -$1.9 million in Q2 2026, -$15.8 million in Q1 2026, and -$6.1 million in Q4 2025.